Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00097344
Status:
TERMINATED
Last Update Posted:
2007-08-23
First Post:
2004-11-22
Brief Title:
The CAT Study Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Sponsor:
Intarcia Therapeutics
Organization:
Intarcia Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Neoplasms Hormone-Dependent |
| Breast Neoplasms |
Keywords:
| Name | View |
|---|---|
| Toremifene | View |
| Aromatase inhibitor | View |
| Atamestane | View |
| Breast neoplasms | View |
| Combined hormonal therapy | View |
| Complete estrogen blockade | View |
| Ductal breast carcinoma | View |
| Estrogen blocker | View |
| Fareston | View |
| Femara | View |
| First line therapy | View |
| Letrozole | View |
| Lobular breast carcinoma | View |
| Locally advanced breast cancer | View |
| Locally recurrent breast cancer | View |
| Maximal estrogen inhibition | View |
| Metastatic breast cancer | View |
| Neoplasms Hormone-dependent | View |
| Receptor-positive | View |
| Stage IIIA breast cancer | View |
| Stage IIIB breast cancer | View |
| Stage IV breast cancer | View |